Safety and Pharmacokinetics of Terbinafine Hydrogen Chloride (HCl) Nail Lacquer in Patients With Onychomycosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00691184|
Recruitment Status : Completed
First Posted : June 5, 2008
Last Update Posted : June 5, 2008
|Condition or disease||Intervention/treatment||Phase|
|Onychomycosis/Onycholysis and Tinea Pedis||Drug: Placebo Drug: Terbinafine Hydrochloride Drug: Terbinafine||Phase 1|
This was a double-blind, randomized, parallel-design, placebo-controlled Phase 1 study comparing 10% Terbinafine HCl Nail Lacquer vs. Placebo Nail Lacquer (i.e., vehicle control). For comparative purposes, the study also included a contemporaneous assessment of 1% Lamisil® Cream (1% terbinafine HCl) and Lamisil® Tablets (terbinafine HCl labeled as 250 mg of terbinafine).
Forty (40) onychomycosis (Groups 1 and 2) and 16 tinea pedis (Group 3) patients were enrolled at 3 study centers. In Group 1, 10% Terbinafine HCl Nail Lacquer, and, in Group 2, its vehicle (0% terbinafine HCl), were applied topically by brushing on a dose volume of approximately 10 μL per nail twice daily for 28 days to each toenail and to 5 mm of adjacent skin. The patients visited the study center on Days 3, 7, 14, 21, and 28 for assessments of clinical signs and to obtain blood samples. In addition, a 24-hour urine sample was collected and assessed on Day 28 and Day 35. Fifty six (56) patients (20 in Group 1, 20 in Group 2, and 16 in Group 3) received a single oral dose of a 250 mg Lamisil® Tablet after a 7-day washout period.
For comparative purposes, the study also evaluated the local and systemic safety, and plasma levels of terbinafine, and its 3 major metabolites (i.e., desmethyl terbinafine, carboxybutyl terbinafine, and desmethyl carboxybutyl terbinafine) following administration of 1% Lamisil® Cream in comparison with 10% Terbinafine HCl Nail Lacquer. In Group 3, approximately 0.5 g of 1% Lamisil® Cream was applied twice a day for 7 days to the area of the foot affected with tinea pedis. The patients visited the study center on Day 3 and on Day 7 for assessments of clinical signs and collection of blood samples. A 24-hour urine sample was collected and assessed on Day 7 and Day 14.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||56 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Double-Blind, Randomized, Parallel Design Study To Assess the Safety and Pharmacokinetics of Terbinafine Hydrogen Cloride (HCl) Nail Lacquer Applied for 28 Days in Patients With Onychomycosis|
|Study Start Date :||February 2005|
|Actual Primary Completion Date :||June 2005|
|Actual Study Completion Date :||December 2005|
Experimental: Group 1
0% Terbinafine HCl Nail Lacquer for 28 days.
0% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
Experimental: Group 2
10% Terbinafine HCl Nail Lacquer.
Drug: Terbinafine Hydrochloride
10% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
Active Comparator: Group 3
1% Lamisil® Cream
Drug: Terbinafine Hydrochloride
1% Terbinafine Hydrochloride Cream, twice a day for 7 days.
Other Name: Lamisil® Cream, 1%
Active Comparator: Group 4
Dose of 250 mg Lamisil® Tablets (Groups 1,2,3) at end of study.
Terbinafine tablet, 250mg, single dose in groups 1,2 and 3 at end of study.
Other Name: Lamisil, 250mg tablet
- The primary safety objective was to determine the safety of 10% Terbinafine HCl Nail Lacquer by assessing local and systemic adverse experiences, changes in vital signs, clinical laboratory test results, physical examinations, and electrocardiogram (ECG) [ Time Frame: 28 Days ]
- To determine plasma levels of terbinafine and its metabolites after administration of 10% Terbinafine HCl Nail Lacquer to toenails, 1% Lamisil® Cream to the infected (i.e., tinea pedis) area of the foot and a single Lamisil® Tablet (250 mg) on Day 35. [ Time Frame: 3, 7, 14, 21 and 28 days and Day 35 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00691184
|United States, New Jersey|
|TKL Research Inc.|
|Paramus, New Jersey, United States, 07652|
|Study Director:||Ming Q Lu, MD., Ph.D.||NexMed (U.S.A.), Inc.|